Genetic mutations may alter treatment courses for patients with MPNs

Alessandro Vannucchi

Traditionally, doctors have used clinical assessments of patients with myeloproliferative neoplasms (MPNs) to evaluate their chances of experiencing future complications, such as thrombosis or survival. However, evidence has recently emerged that certain genetic mutations can alter a patient’s chance of experiencing these complications. At the Myeloproliferative Neoplasms Advances Day 2017 in London, UK, Alessandro Vannucchi, MD, of the University of Florence, Florence, Italy, discusses some of these known mutations, and how doctors can use their presence or absence to decide the best course of action for the patient.